Reforgene Medicine's β-Thalassemia Gene Therapy RM001 Achieves Major Phase II Milestone: All Subjects Transfusion-Free Over 1 Year as Novel Target Shows Best-in-Class Potential

GUANGZHOU, China — Oct. 21, 2026

Reforgene Medicine announced Monday that its gene-editing therapy RM001 has achieved a major milestone in a pivotal Phase II clinical trial for transfusion-dependent β-thalassemia: all 28 enrolled subjects have become transfusion-free, with follow-up exceeding one year. The results position RM001 among the most advanced clinical programs globally targeting a novel genetic switch for the blood disorder.

In total, 47 patients have received the therapy across all study cohorts, and every one of them has rebuilt functional blood-cell production and shed their dependence on regular transfusions. The longest follow-up now stretches to five years — a duration that, if sustained, would represent a durable functional cure for a disease that otherwise demands lifelong transfusion regimens.

The data, disclosed at the company's Guangzhou headquarters, underscore the growing competitive intensity in gene-editing therapies for inherited blood disorders — a field once dominated by CRISPR Therapeutics and Vertex Pharmaceuticals' Casgevy, the first CRISPR-based treatment to win regulatory approval. RM001, however, takes a different biological aim. Rather than disabling the BCL11A gene to indirectly raise fetal hemoglobin, Reforgene's therapy directly targets the HBG1/2 promoter — the genetic control panel that governs production of gamma-globin, the protein building block of fetal hemoglobin. The approach mimics a naturally occurring protective mutation found in certain individuals who maintain high fetal-hemoglobin levels throughout life with no adverse health effects.

By leaving BCL11A intact, the company argues, RM001 preserves the gene's normal role in blood-cell regulation while still reactivating fetal hemoglobin production at therapeutic levels. That design choice, Reforgene says, provides both the efficacy floor and the long-term safety profile that distinguish the program from competitors.

A rapid path to transfusion freedom

The Phase II trial, launched in 2025, enrolled 28 patients with more complex baseline characteristics than those in earlier studies. As of October 2026, all 28 have achieved sustained transfusion independence. Key recovery metrics — including time to neutrophil engraftment, platelet engraftment, and transfusion cessation — compared favorably with peer products, the company said. The median time to stopping transfusions was approximately 18 days, and hemoglobin levels stabilized across the cohort.

On safety, Reforgene reported no product-related serious adverse events through the current follow-up window. No cases of hepatic veno-occlusive disease, death, treatment discontinuation, or malignancy were observed — a profile the company said remained consistent with earlier Phase I and investigator-initiated trial data.

Editing efficiency and iron-overload relief

RM001 is a single-dose therapy. Physicians extract a patient's own CD34+ hematopoietic stem cells, edit them ex vivo using CRISPR technology, and reinfuse the modified cells. The company reported in vitro editing efficiency of 80% to 90% at the HBG1/2 promoter. After reinfusion, bone-marrow editing chimerism — the share of edited cells taking up residence in the marrow — has held steady between 65.6% and 85.4% over time, indicating that the corrected stem cells persist and continue producing high-fetal-hemoglobin red blood cells.

That editing durability carries clinical implications beyond hemoglobin levels. In β-thalassemia, ineffective blood-cell production drives the body to absorb excess iron, which accumulates in the liver, heart, and endocrine organs. In a combined Phase I and investigator-initiated trial involving 19 subjects, more than half saw serum ferritin — a key marker of iron burden — decline to low-risk levels after treatment, eliminating the need for additional iron-chelation therapy. The finding suggests that RM001 does not merely correct lab values but may interrupt the cascade of organ damage caused by iron overload.

Expanding the patient pool

The program has also broadened the types of patients it can treat. Reforgene completed China's first gene-editing treatment of an adult thalassemia patient and the country's first such procedure in a splenectomized thalassemia patient — both of whom achieved transfusion independence. The company said the results demonstrate that RM001's benefits span age groups and disease backgrounds, potentially widening its addressable patient population.

RM001 received an implicit clinical-trial license from China's National Medical Products Administration in November 2022, making it the first HBG1/2 promoter–targeted gene-editing therapy for thalassemia to enter clinical development in China and, according to publicly disclosed data, the first such program globally. Reforgene has presented results at major hematology conferences including the European Hematology Association, the American Society of Hematology, and the American Society of Gene and Cell Therapy annual meetings.

Platform and pipeline

Reforgene built RM001 on its proprietary "TIPBAIG" data-driven technology platform, which houses multiple gene-editing tool sets with independent intellectual-property protection. The company said the platform supports end-to-end capabilities spanning tool innovation, target validation, drug-development research, animal-model evaluation, and efficacy and safety assessment.

Looking ahead, Reforgene plans to advance RM001 into late-stage clinical development and regulatory filings, while also expanding into sickle cell disease — a related hemoglobin disorder with significant unmet need, particularly in sub-Saharan Africa and among African-American populations in the United States. The company noted it is the only developer worldwide with clinical-stage gene-editing programs for both α-thalassemia and β-thalassemia, having already achieved what it described as the world's first curative gene-editing treatment for α-thalassemia.

β-thalassemia is an inherited blood disorder prevalent across the Mediterranean, the Middle East, South Asia, Southeast Asia, and southern China. Patients with the transfusion-dependent form cannot produce enough functional β-globin, forcing them into lifelong transfusion schedules that carry risks of iron overload, organ damage, and early death. The only established curative option — allogeneic hematopoietic stem-cell transplantation — is limited by donor-matching requirements, peri-transplant risks, and long-term complications.

RM001 remains an investigational drug and has not received marketing approval. The data disclosed are from clinical trials and may not reflect final therapeutic outcomes, the company cautioned.